Epitopes mapping of SARS-CoV-2 virus to T lymphocytes and Spike protein receptor to B lymphocytes

  • Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
  • Total publications:1 publications

Grant number: 2020/05256-7

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $71,132.58
  • Funder

    Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
  • Principle Investigator

    Pending
  • Research Location

    Brazil, Americas
  • Lead Research Institution

    Universidade de São Paulo
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The emerging SARS-CoV-2 virus appeared in China, with easy spread and significant lethality. In less than three months of its identification it has already caused more than 35,000 deaths worldwide and with an increasing number of fatalities. As it is a new virus introduced in the human population, it is not known if there is an immune population; it has easy spread and lethality varies from 1 to 16% according to country, age group and comorbidities. In the absence of a specific vaccine or treatment, the pandemic is paralyzing entire continents. The entry of all coronaviruses into host cells is known to be mediated by the glycoprotein Spike, a potential therapeutic target, especially the region of the receptor receptor domain. The knowledge of the cellular response to this virus is still little known. Therefore, this knowledge is of immediate relevance. In this project, we aim to map the epitopes of T and B lymphocytes recognized by cells and antibodies of convalescent COVID-19 patients, starting from the complete sequence for T epitopes and focusing on the Spike protein receptor for B lymphocytes. These data may assist in the development of vaccines and immunotherapeutics in the medium term.

Publicationslinked via Europe PMC

Last Updated:37 minutes ago

View all publications at Europe PMC

Time-dependent contraction of the SARS-CoV-2-specific T-cell responses in convalescent individuals.